We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMEA: Risk Management Plans Should Address Vaccine Concerns
EMEA: Risk Management Plans Should Address Vaccine Concerns
November 12, 2008
Vaccine safety concerns that emerge before marketing should be investigated during preauthorization and addressed in the manufacturer’s risk management plan (RMP), according to a European Medicines Agency (EMEA) draft guideline.